Weath­er­ing the storm: An­oth­er biotech braves Covid-19 in up­sized IPO

Zen­tal­is isn’t the on­ly biotech to de­fy ex­pec­ta­tions as fi­nan­cial mar­kets across the globe roil from the shock of the coro­n­avirus pan­dem­ic. Keros Ther­a­peu­tics has man­aged to ex­e­cute an IPO, hit­ting the top end of its pric­ing range and sell­ing more shares than orig­i­nal­ly en­vi­sioned, as it shep­herds its lead drug in­to mid-stage de­vel­op­ment.

The Lex­ing­ton, Mass­a­chu­setts-based com­pa­ny’s pipeline of drugs tar­get a fam­i­ly of pro­teins called trans­form­ing growth fac­tor-be­ta (TGF-β), sig­nal­ing path­ways that reg­u­late blood cell and platelet pro­duc­tion, and growth, re­pair, and main­te­nance of mus­cle and bone.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.